Log In
Print this Print this

JNJ-56914845 (formerly 2336805, GSK2336805)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1 infection
Regulatory Designation


Johnson & Johnson

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today